For immunochemical detection of the IP receptor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

IP Receptor (human) Polyclonal Antibody

Item No. 10005518

Technical Information
Synonyms
  • PGI2 Receptor
  • Prostacyclin Receptor
  • Prostaglandin I2 Receptor
Immunogen
Synthetic peptide from the N-terminal region of human IP receptor
MW
~42 kDa
500 µl of peptide affinity-purified polyclonal antibody
Storage Buffer
PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide
Host
Rabbit
Applications
WB
Cross Reactivity
(+) IP Receptor
Species Reactivity
(+) Human(+) Mouse
UniProt Accession №
P43119
Origin
Animal/Rabbit
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    The IP Receptor is a class A rhodopsin-like G protein-coupled receptor that mediates the actions of prostaglandin I2 (PGI2).1 The C-terminal intracellular tail of the IP receptor undergoes isoprenylation and palmitoylation that results in anchoring of the tail to the plasma membrane. The IP receptor is expressed in platelets and vascular smooth muscle cells and in the aorta, lungs, heart, and kidneys.1,2 It signals through G proteins in a cell type- and expression-dependent manner and is involved in cardiovascular, inflammatory, and immune functions, as well as the pain response.1,3,4,5,6 An arginine-to-cysteine mutation at position 212 in the IP receptor inhibits its ability to activate adenylyl cyclase, which leads to increased platelet aggregation ex vivo and increases disease severity and the incidence of cardiovascular events in patients with a high risk of cardiovascular disease.7 The human IP receptor is N-terminally truncated by 28 amino acids compared with the murine receptor.2,8 Cayman’s IP Receptor (human) Polyclonal Antibody can be used for Western blot (WB). The antibody recognizes the IP receptor at approximately 42 kDa from human and mouse samples.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stitham, J., Arehart, E.J., Gleim, S.R., et alHuman prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat. 82(1-4), 95-108 (2007).

    2. Nakagawa, O., Tanaka, I., Usui, T., et alMolecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90, 1643-1647 (1994).

    3. Cheng, Y., Austin, S.C., Rocca, B., et alRole of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567), 539-541 (2002).

    4. Cui, Y., Kataoka, Y., Satoh, T., et alProtective effect of prostaglandin I2 analogs on ischemic delayed neuronal damage in gerbils. Biochem. Biophys. Res. Commun. 265(2), 301-304 (1999).

    5. Norlander, A.E., and Peebles, R.S.J. Prostaglandin I2 and T regulatory cell function: Broader impacts. DNA Cell Biol. 40(10), 1231-1234 (2021).

    6. Murata, T., Ushikubi, F., Matsuoka, T., et alAltered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388(6643), 678-682 (1997).

    7. Arehart, E.J., Stitham, J., Asselbergs, F.W., et alAcceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition. Circ. Res. 102(8), 986-993 (2008).

    8. Namba, T., Oida, H., Sugimoto, Y., et alcDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. The Journal of Biological Chemisty 269, 9986-9992 (1994).